Bilix Co., Ltd.
🇰🇷South Korea
A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants
Phase 1
Completed
- Conditions
- Ischemia-reperfusion Injury
- Interventions
- Drug: BX-001N Part 1Drug: BX-001N Part 2Drug: Placebo
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Bilix Co.,Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT06097702
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath